Ashish Patil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ashish Patil has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Alvaro Avivar‐Valderas
Division of Hematology and Oncology, Department of Medicine, Department of Otolaryngology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY
1 shared publication- Clement T. Y. Chan
Department of Biomedical Engineering, University of North Texas, Denton, TX, USA
1 shared publication Dan Su
Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA
1 shared publication- Julio A. Aguirre-Ghiso
Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
1 shared publication Lauren Endres
College of Nanoscale Science and Engineering, University at Albany, State University of New York, Albany, NY
1 shared publicationMaria Soledad Sosa
Division of Hematology and Oncology, Department of Medicine, Department of Otolaryngology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY
1 shared publication
Latest Publications
- Open Access
- 4 February 2013
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 5 (3) , 366-383
A human tRNA methyltransferase 9‐like protein prevents tumour growth by regulating LIN9 and HIF1‐α
Emerging evidence points to aberrant regulation of translation as a driver of cell transformation in cancer. Given the direct control of translation by tRNA modifications, tRNA modifying enzymes may function as regulators of cancer progression. Here, we show that a tRNA methyltransferase 9‐like ( hTRM9L/KIAA1456 ) mRNA is down‐regulated in breast, bladder, colorectal, cervix and testicular carcinomas. In the aggressive SW620 and HCT116 colon carcinoma cell lines, hTRM9L is silenced and its re‐expression and methyltransferase activity dramatically suppressed tumour growth in vivo . This growth inhibition was linked to decreased proliferation, senescence‐like G0/G1‐arrest and up‐regulation of the RB interacting protein LIN9. Additionally, SW620 cells re‐expressing hTRM9L did not respond to hypoxia via HIF1‐α‐dependent induction of GLUT1. Importantly, hTRM9L ‐negative tumours were highly sensitive to aminoglycoside antibiotics and this was associated with altered tRNA modification levels compared to antibiotic resistant hTRM9L ‐expressing SW620 cells. Our study links hTRM9L and tRNA modifications to inhibition of tumour growth via LIN9 and HIF1‐α‐dependent mechanisms. It also suggests that aminoglycoside antibiotics may be useful to treat hTRM9L‐deficient tumours.
- 4 February 2013
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 5 (3) , 366-383
Open AccessA human tRNA methyltransferase 9‐like protein prevents tumour growth by regulating LIN9 and HIF1‐α
Emerging evidence points to aberrant regulation of translation as a driver of cell transformation in cancer. Given the direct control of translation by tRNA modifications, tRNA modifying enzymes may function as regulators of cancer progression. Here, we show that a tRNA methyltransferase 9‐like ( hTRM9L/KIAA1456 ) mRNA is down‐regulated in breast, bladder, colorectal, cervix and testicular carcinomas. In the aggressive SW620 and HCT116 colon carcinoma cell lines, hTRM9L is silenced and its re‐expression and methyltransferase activity dramatically suppressed tumour growth in vivo . This growth inhibition was linked to decreased proliferation, senescence‐like G0/G1‐arrest and up‐regulation of the RB interacting protein LIN9. Additionally, SW620 cells re‐expressing hTRM9L did not respond to hypoxia via HIF1‐α‐dependent induction of GLUT1. Importantly, hTRM9L ‐negative tumours were highly sensitive to aminoglycoside antibiotics and this was associated with altered tRNA modification levels compared to antibiotic resistant hTRM9L ‐expressing SW620 cells. Our study links hTRM9L and tRNA modifications to inhibition of tumour growth via LIN9 and HIF1‐α‐dependent mechanisms. It also suggests that aminoglycoside antibiotics may be useful to treat hTRM9L‐deficient tumours.